GLP-1RAs were linked to fewer asthma exacerbations and emergency visits in teens with obesity, suggesting potential ...

Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...

Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history. Dupilumab was shown to consistently ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

Please provide your email address to receive an email when new articles are posted on . Asthma exacerbation rates ranged from 0.91 to 1.37 for the placebo group and from 0.32 to 0.58 for the dupilumab ...

Asian woman using a pressurized cartridge inhaler extended pharynx, Bronchodilator CHRONICLE investigators reported results of a patient survey on common asthma triggers at ACAAI 2021. The following ...

A novel biologic for severe asthma reduced exacerbations by 56%, according to a study published Wednesday in The New England Journal of Medicine. A novel biologic for severe asthma reduced ...

Researchers at Mass General Brigham and Karolinska Institutet have identified a new method to predict asthma exacerbations ...

The US Food and Drug Administration (FDA) has granted priority review for the biologic tezepelumab (AstraZeneca/Amgen) for treatment of severe asthma. The announcement was reported July 8, just days ...